Back to News
Market Impact: 0.05

Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting

Source: PR Newswire

Healthcare & Biotech

The provided text only identifies Innovent Biologics (HKEX: 01801) as a biopharmaceutical company developing, manufacturing and commercializing medicines across oncology, cardiovascular and metabolic diseases. No specific clinical, financial, regulatory or product-development announcement is included in the article excerpt.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

neutral

Sentiment Score

0.00

More News

From AllMind Research

Browse all research